Germany Antibody Drug Conjugates Contract Manufacturing Market Size & Outlook
Related Markets
Germany antibody drug conjugates contract manufacturing market highlights
- The Germany antibody drug conjugates contract manufacturing market generated a revenue of USD 542.3 million in 2024 and is expected to reach USD 998.9 million by 2030.
- The Germany market is expected to grow at a CAGR of 10.8% from 2025 to 2030.
- In terms of segment, myeloma was the largest revenue generating condition in 2024.
- Myeloma is the most lucrative condition segment registering the fastest growth during the forecast period.
Antibody drug conjugates contract manufacturing market data book summary
| Market revenue in 2024 | USD 542.3 million |
| Market revenue in 2030 | USD 998.9 million |
| Growth rate | 10.8% (CAGR from 2025 to 2030) |
| Largest segment | Myeloma |
| Fastest growing segment | Myeloma |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Myeloma, Lymphoma, Breast Cancer |
| Key market players worldwide | Sterling Check Corp, Recipharm, Lonza Group Ltd, Catalent Inc, Sartorius AG, WuXi Biologics (Cayman) Inc, Samsung BioLogics, Piramal Healthcare, AbbVie Inc, Merck KGaA |
Other key industry trends
- In terms of revenue, Germany accounted for 6.1% of the global antibody drug conjugates contract manufacturing market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antibody drug conjugates contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 998.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Contract Manufacturing Market Scope
Antibody Drug Conjugates Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Piramal Healthcare | View profile | 5001-10000 | Mumbai, Maharashtra, India, Asia | http://www.piramalpharmasolutions.com |
| Sterling Check Corp | View profile | 5700 | 6150 Oak Tree Boulevard, Suite 490, Independence, OH, United States, 44131 | https://www.sterlingcheck.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| Sartorius AG | View profile | 14338 | Otto-Brenner-Strasse 20, Gottingen, NI, Germany, 37079 | https://www.sartorius.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
Germany antibody drug conjugates contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibody drug conjugates contract manufacturing market will help companies and investors design strategic landscapes.
Myeloma was the largest segment with a revenue share of 54.9% in 2024. Horizon Databook has segmented the Germany antibody drug conjugates contract manufacturing market based on myeloma, lymphoma, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Germany is known for its high-quality products, and the increased emphasis on quality is expected to further improve the demand for outsourcing in Germany, which is anticipated to support the market growth in the country.
Germany's biopharmaceutical companies are actively involved in antibody-drug conjugate research. For example, in September 2022, Tubulis GmbH, in collaboration with the German Cancer Consortium (DKTK), the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), and the LMU Klinikum Munich conducted research that demonstrated that antibody drug conjugates were highly effective and safe in preclinical in vivo models of Acute Myeloid Leukemia (AML).
Such research is expected to improve the development of new antibody-drug conjugates in the country, thereby supporting market growth over the forecast period. The presence of the Federal Ministry for Economic Affairs and Energy, which is involved in undertaking initiatives such as "Health-Made in Germany" to identify possible partners for contract manufacturing, is anticipated to drive market growth.
Reasons to subscribe to Germany antibody drug conjugates contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Germany antibody drug conjugates contract manufacturing market databook
-
Our clientele includes a mix of antibody drug conjugates contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany antibody drug conjugates contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Germany antibody drug conjugates contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Germany antibody drug conjugates contract manufacturing market size, by condition, 2018-2030 (US$M)
Germany Antibody Drug Conjugates Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
